Next Article in Journal
Nattokinase: An Oral Antithrombotic Agent for the Prevention of Cardiovascular Disease
Previous Article in Journal
Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study
Previous Article in Special Issue
Allostatic Load and Preterm Birth
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(3), 522; doi:10.3390/ijms18030522

The Endothelin Type A Receptor as a Potential Therapeutic Target in Preeclampsia

Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS 39216, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Philip Newton Baker
Received: 25 January 2017 / Revised: 16 February 2017 / Accepted: 25 February 2017 / Published: 28 February 2017
(This article belongs to the Special Issue Prediction, Diagnostics and Prevention of Pregnancy Complications)
View Full-Text   |   Download PDF [543 KB, uploaded 28 February 2017]   |  

Abstract

Preeclampsia (PE) is a disorder of pregnancy typically characterized by new onset hypertension after gestational week 20 and proteinuria. Although PE is one of the leading causes of maternal and perinatal morbidity and death worldwide, the mechanisms of the pathogenesis of the disease remain unclear and treatment options are limited. However, there is increasing evidence to suggest that endothelin-1 (ET-1) plays a critical role in the pathophysiology of PE. Multiple studies report that ET-1 is increased in PE and some studies report a positive correlation between ET-1 and the severity of symptoms. A number of experimental models of PE are also associated with elevated tissue levels of prepro ET-1 mRNA. Moreover, experimental models of PE (placental ischemia, sFlt-1 infusion, Tumor necrosis factor (TNF) -α infusion, and Angiotensin II type 1 receptor autoantibody (AT1-AA) infusion) have proven to be susceptible to Endothelin Type A (ETA) receptor antagonism. While the results are promising, further work is needed to determine whether ET antagonists could provide an effective therapy for the management of preeclampsia. View Full-Text
Keywords: preeclampsia; pregnancy; hypertension; endothelin; endothelium; placenta; cardiovascular; blood pressure; vascular smooth muscle preeclampsia; pregnancy; hypertension; endothelin; endothelium; placenta; cardiovascular; blood pressure; vascular smooth muscle
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Bakrania, B.; Duncan, J.; Warrington, J.P.; Granger, J.P. The Endothelin Type A Receptor as a Potential Therapeutic Target in Preeclampsia. Int. J. Mol. Sci. 2017, 18, 522.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top